在小鼠模型中用超极化13C-丙酮酸MR波谱和18F-FDG PET/CT成像在体内评估卵巢肿瘤对酪氨酸激酶抑制剂帕唑帕尼的治疗反应
研究在14只卵巢癌SKOV3荷瘤裸鼠中比较帕唑帕尼与溶媒对照,于治疗前、治疗后2天和2周行T2加权MRI、超极化13C-丙酮酸动态MR波谱及18F-FDG PET/CT。帕唑帕尼抑制肿瘤生长,治疗后2天乳酸/丙酮酸+乳酸比值较治疗前升高,而对照组及18F-FDG PET/CT未见此变化,提示超极化13C-丙酮酸MR波谱可能作为早期疗效指标。
要点
- 帕唑帕尼组肿瘤重量0.054 g±0.041,低于对照组0.223 g±0.112(P<.05)。
- 帕唑帕尼治疗后2天乳酸/丙酮酸+乳酸比值0.46±0.07,高于治疗前0.31±0.14(P<.05)。
- 对照组及18F-FDG PET/CT未见上述代谢变化,提示MR波谱可能早于FDG PET/CT反映疗效。
核心结论
- 超极化13C-丙酮酸MR波谱可能作为卵巢癌对酪氨酸激酶(血管生成)抑制剂帕唑帕尼治疗反应的早期指标,即使在18F-FDG PET/CT未提示反应时也是如此。
研究设计与样本
- 动物实验;14只雌性裸鼠注射2×10^6人卵巢SKOV3肿瘤细胞,17天后开始溶媒或帕唑帕尼(每只2.5 mg,口服,隔日一次)治疗;帕唑帕尼组6只、对照组7只;于治疗前、治疗后2天及2周行纵向T2加权MR成像、超极化丙酮酸动态MR波谱及18F-FDG PET/CT成像。
关键影像表现/征象
- 帕唑帕尼组肿瘤重量0.054 g±0.041,对照组0.223 g±0.112(P<.05)。
- 帕唑帕尼治疗后2天乳酸/丙酮酸+乳酸比值0.46±0.07,高于治疗前0.31±0.14(P<.05;治疗后6个肿瘤、治疗前7个肿瘤)。
- 对照组及18F-FDG PET/CT成像未观察到该变化。
诊断标准与关键数值
- 以乳酸/丙酮酸+乳酸比值评估丙酮酸到乳酸的转化;帕唑帕尼治疗后2天0.46±0.07 vs 治疗前0.31±0.14(P<.05)。
临床应用与阅片要点
- 作者认为超极化13C-丙酮酸MR波谱可能作为卵巢癌对帕唑帕尼等酪氨酸激酶(血管生成)抑制剂治疗反应的早期指标。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Purpose To assess in a mouse model whether early or late components of glucose metabolism, exemplified by fluorine 18 (18F) fluorodeoxyglucose (FDG) positron emission tomography (PET) and hyperpolarized carbon 13 (13C)-pyruvate magnetic resonance (MR) spectroscopy, can serve as indicators of response in ovarian cancer to multityrosine kinase inhibitor pazopanib. Materials and Methods In this Animal Care and Use Committee approved study, 17 days after the injection of 2 × 106 human ovarian SKOV3 tumors cells into 14 female nude mice, treatment with vehicle or pazopanib (2.5 mg per mouse peroral every other day) was initiated. Longitudinal T2-weighted MR imaging, dynamic MR spectroscopy of hyperpolarized pyruvate, and 18F-FDG PET/computed tomographic (CT) imaging were performed before treatment, 2 days after treatment, and 2 weeks after treatment. Results Pazopanib inhibited ovarian tumor growth compared with control (0.054 g ± 0.041 vs 0.223 g ± 0.112, respectively; six mice were treated with pazopanib and seven were control mice; P < .05). Significantly higher pyruvate-to-lactate conversion (lactate/pyruvate + lactate ratio) was found 2 days after treatment with pazopanib than before treatment (0.46 ± 0.07 vs 0.31 ± 0.14, respectively; P < .05; six tumors after treatment, seven tumors before treatment). This was not observed with the control group or with 18F-FDG PET/CT imaging. Conclusion The findings suggest that hyperpolarized 13C-pyruvate MR spectroscopy may serve as an early indicator of response to tyrosine kinase (angiogenesis) inhibitors such as pazopanib in ovarian cancer even when 18F-FDG PET/CT does not indicate a response. © RSNA, 2017 Online supplemental material is available for this article.
引用
- Ravoori MK, Singh SP, Lee J, et al. In Vivo Assessment of Ovarian Tumor Response to Tyrosine Kinase Inhibitor Pazopanib by Using Hyperpolarized 13C-Pyruvate MR Spectroscopy and 18F-FDG PET/CT Imaging in a Mouse Model. Radiology. 2017. PMID: 28707963. doi:10.1148/radiol.2017161772
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。